Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

HANSIZHUANG (serplulimab) is the world’s first anti-PD-1 mAb for first-line treatment of ES- SCLC – HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES- SCLC – HANSIZHUANG (serplulimab) has…